Researchers at Vanderbilt University have developed a promising therapeutic strategy aimed at overcoming resistance to immunotherapy in patients with advanced melanoma lacking the BRAF mutation. Led by Professor Emerita of Pharmacology Ann Richmond, the study outlines a three-drug combination that may re-sensitize resistant tumors, offering new hope for patients who have not responded to existing treatments.
In their research published in Nature Communications in January 2026, the team investigated the efficacy of a combination therapy that includes a low dose of the MEK inhibitor trametinib, the multi-kinase inhibitor rigosertib, and a CD40 agonist. This innovative approach enhances immune activity while suppressing tumor-promoting immune cells, thereby shifting the tumor microenvironment toward a more favorable immune response.
Richmond highlighted the significance of their findings, stating, “While CD40 therapy can be helpful for the treatment of melanoma, it also induces CD11b + B regulatory cells that suppress the T cell response to tumors. We showed that combining CD40 therapy with trametinib and rigosertib prevents the induction of these B regulatory cells.”
The problem of resistance to immune checkpoint inhibitors (ICIs) is prevalent in metastatic melanoma, particularly in tumors that develop immune-suppressive microenvironments. Current treatments often fail, leaving patients with limited options. Findings from the study indicate that while CD40 agonists activate immune cells, they can also inadvertently expand suppressive regulatory B cells. By combining CD40 activation with MEK and PI3K inhibition, the researchers effectively blocked the expansion of these suppressive cells, thereby maintaining the benefits of CD40 stimulation.
Key Findings and Implications
In preclinical mouse models of melanoma, the triple therapy not only inhibited tumor growth but also restored the tumors’ responsiveness to ICI treatment. The researchers identified several critical outcomes from their study:
– **B cells as a resistance mechanism**: Treatment with CD40 therapy alone led to the induction of regulatory B cells, which dampen T cell-mediated tumor immunity.
– **Triple combination prevents immune suppression**: Co-treatment with trametinib and rigosertib effectively blocked the induction of regulatory B cells, allowing immune responses to proceed.
– **ICIs regain effectiveness**: The drug combination slowed tumor progression and re-sensitized resistant melanomas to anti-PD-1 therapy.
The significance of this research is amplified by the fact that all three agents have been approved by the U.S. Food and Drug Administration or are already in clinical trials. This may expedite their availability for patient testing, offering a potentially faster route to treatment for those who have progressed on ICIs.
Richmond and her team view their findings as a new opportunity to enhance antitumor immunity in patients with melanoma that no longer responds to existing immunotherapies. “This approach provides a new route to enhance antitumor immunity in patients with tumors that no longer respond to immunotherapy,” she stated.
The project involved a multidisciplinary collaboration, including fellow Vanderbilt principal investigators Vivian Weiss, Doug Johnson, and Qi Liu. Chi Yan, a former Research Assistant Professor of Pharmacology, served as the first author and plans to continue this line of investigation at the University of Manitoba.
Funding and Open Access
This groundbreaking research received support from the National Cancer Institute, the Department of Veterans Affairs, and a Lloyd Foundation Melanoma Research Grant. The study was published under an open access agreement negotiated by Vanderbilt University’s Jean and Alexander Heard Libraries, ensuring that the findings are freely accessible to researchers and the public worldwide.
The implications of this research extend beyond the laboratory, potentially transforming treatment protocols for melanoma patients facing limited options. As the study progresses toward clinical trials, the hope is that this innovative combination therapy will offer renewed hope for those battling this challenging disease.
